

Luc Mouthon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7103481/publications.pdf>

Version: 2024-02-01

49
papers

3,359
citations

159358

30
h-index

189595

50
g-index

52
all docs

52
docs citations

52
times ranked

3632
citing authors

#	ARTICLE	IF	CITATIONS
1	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.5	410
2	Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. <i>Blood</i> , 2003, 101, 758-765.	0.6	280
3	The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. <i>Arthritis and Rheumatism</i> , 2009, 60, 1831-1839.	6.7	179
4	Assessing disability and quality of life in systemic sclerosis: Construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. <i>Arthritis and Rheumatism</i> , 2007, 57, 94-102.	6.7	178
5	Selective Oxidation of DNA Topoisomerase 1 Induces Systemic Sclerosis in the Mouse. <i>Journal of Immunology</i> , 2009, 182, 5855-5864.	0.4	176
6	Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. <i>Rheumatology</i> , 2012, 51, 460-467.	0.9	147
7	Intravenous Immunoglobulin Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection: A Retrospective Study of 10 Patients and Review of the Literature. <i>Clinical Infectious Diseases</i> , 2013, 56, 968-977.	2.9	144
8	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1009-1015.	0.5	112
9	Pathogenesis of giant cell arteritis: More than just an inflammatory condition?. <i>Autoimmunity Reviews</i> , 2010, 9, 635-645.	2.5	110
10	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.5	107
11	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. <i>BMJ Open</i> , 2013, 3, e003563.	0.8	104
12	Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. <i>Journal of Rheumatology</i> , 2008, 35, 1064-72.	1.0	99
13	Scleroderma Renal Crisis. <i>Journal of Rheumatology</i> , 2014, 41, 1040-1048.	1.0	79
14	Mechanisms of action of intravenous immunoglobulin. <i>Transfusion and Apheresis Science</i> , 2017, 56, 45-49.	0.5	78
15	Systemic Sclerosis-Associated Myopathy. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 268-282.	1.8	77
16	Recommendations for the care of oral involvement in patients with systemic sclerosis. <i>Arthritis Care and Research</i> , 2011, 63, 1126-1133.	1.5	68
17	Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. <i>Journal of Autoimmunity</i> , 2011, 36, 9-15.	3.0	67
18	Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor β^2 and Activate Fibroblasts. <i>Arthritis and Rheumatology</i> , 2017, 69, 1078-1089.	2.9	59

#	ARTICLE	IF	CITATIONS
19	Endothelin-1 expression in scleroderma renal crisis†. <i>Human Pathology</i> , 2011, 42, 95-102.	1.1	58
20	Pathophysiology of systemic sclerosis: State of the art in 2014. <i>Presse Medicale</i> , 2014, 43, e267-e278.	0.8	53
21	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	0.9	53
22	Personalized Physical Therapy Versus Usual Care for Patients With Systemic Sclerosis: A Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2017, 69, 1050-1059.	1.5	52
23	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2017, 56, 1302-1311.	0.9	51
24	Intravenous Immunoglobulin Expands Regulatory T Cells in Autoimmune Rheumatic Disease. <i>Journal of Rheumatology</i> , 2012, 39, 450-451.	1.0	48
25	Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. <i>Presse Medicale</i> , 2014, 43, e345-e363.	0.8	42
26	IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 596-605.	0.5	41
27	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	2.9	41
28	French recommendations for the management of systemic sclerosis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 322.	1.2	37
29	Levamisole-induced vasculopathy: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 921-926.	1.6	35
30	mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G. <i>Rheumatology</i> , 2018, 57, 1011-1020.	0.9	33
31	Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients. <i>Scientific Reports</i> , 2014, 4, 5672.	1.6	31
32	Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016, 68, 1195-1200.	1.5	31
33	Proteomes of umbilical vein and microvascular endothelial cells reflect distinct biological properties and influence immune recognition. <i>Proteomics</i> , 2012, 12, 2547-2555.	1.3	28
34	Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: Targeting endothelin-1 receptor to control proliferation. <i>Autoimmunity Reviews</i> , 2017, 16, 398-406.	2.5	28
35	Identification of target antigens of anti-endothelial cell antibodies in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides: A proteomic approach. <i>Clinical Immunology</i> , 2014, 153, 123-135.	1.4	25
36	Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: Toward contractile versus synthetic phenotypes. <i>Proteomics</i> , 2016, 16, 2637-2649.	1.3	25

#	ARTICLE	IF	CITATIONS
37	Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients. <i>Autoimmunity Reviews</i> , 2020, 19, 102431.	2.5	24
38	Contribution of antiferritin antibodies to diagnosis of giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1269-1270.	0.5	23
39	Role of B-Cell in the Pathogenesis of Systemic Sclerosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
40	Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 234-240.	1.0	14
41	Pathophysiology of systemic sclerosis. <i>Presse Medicale</i> , 2021, 50, 104087.	0.8	14
42	Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study. <i>Clinical Immunology</i> , 2020, 215, 108419.	1.4	13
43	Treatment of systemic sclerosis. <i>Presse Medicale</i> , 2021, 50, 104088.	0.8	10
44	Extra-haematological manifestations related to human parvovirus B19 infection: retrospective study in 25 adults. <i>BMC Infectious Diseases</i> , 2018, 18, 302.	1.3	9
45	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. <i>JMIR Research Protocols</i> , 2020, 9, e16799.	0.5	7
46	Proteomic Analysis of Human Scleroderma Fibroblasts Response to Transforming Growth Factor- β . <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800069.	0.8	5
47	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 1300-1310.	1.5	4
48	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021, 22, 856.	0.7	4
49	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. <i>Pilot and Feasibility Studies</i> , 2022, 8, 45.	0.5	3